Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + cobimetinib after first-line immunotherapy for advanced melanoma
2017-000504-20Phase 2Terminated
- Sponsor
- Fondazione Melanoma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in melanoma, sponsored by Fondazione Melanoma. Primary endpoint: overall survival. Started May 2021; status: terminated.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-000504-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000504-20.